2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2558

The Role of Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1) in Collagen-Induced Arthritis

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2536

The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2354

The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2330

The Turkish Validity and Reliability of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL)

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2320

The Use of Doppler Ultrasound in Patients with Rheumatoid Arthritis Improves Patient Understanding of Disease and Adherence to Treatment and Alters Clinical Practice

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2915

The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2539

The Validity and Reliability of Turkish Version of the Jenkins Sleep Scale in Rheumatoid Arthritis

Research Methodology Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 2215

Ticagrelor Regulates Osteoblast and Osteoclast Function and Promotes Bone Formation in Vivo By Increasing Adenosine Levels

Biology and Pathology of Bone and Joint: Bone Remodeling and Metabolism

9:00AM-11:00AM: Abstract Number: 2920

Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2372

Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2581

TNF-Alpha Receptor II Signaling Plays an Important Role in Maintaining the Expression of Forkhead Box P3 in Murine Regulatory T Cells

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 3061

Tocilizumab in Refractory Takayasu Arteritis. a Multicenter Study

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 3042

Tocilizumab in Refractory Uveitis Associated with Behçet’s Disease. Multicenter Study of 7 Patients.

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2750

Tocilizumab Is Effective As 1st, 2nd and 3rd-Line Biologic DMARD in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2801

Tofacitinib Suppresses Lymphocytic Infiltration in the Salivary Gland of Non-Obese Diabetic Mice; The Animal Model of Sjögren’s Syndrome

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].